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Abstract
A novel avian influenza virus H7N9 infection occurred among human populations since
2013. Although the lack of sustained human-to-human transmission limited the epidemics
caused by H7N9, the late presentation of most patients and the emergence of neuramini-
dase-resistant strains made the development of novel antiviral strategy against H7N9 in
urgent demands. In this study, we evaluated the potential of pamidronate, a pharmacologi-
cal phosphoantigen that can specifically boost human Vδ2-T-cell, on treating H7N9 virus-
infected humanized mice. Our results showed that intraperitoneal injection of pamidronate
could potently decrease the morbidity and mortality of H7N9-infected mice through control-
ling both viral replication and inflammation in affected lungs. More importantly, pamidronate
treatment starting from 3 days after infection could still significantly ameliorate the severity
of diseases in infected mice and improve their survival chance, whereas orally oseltamivir
treatment starting at the same time showed no therapeutic effects. As for the mechanisms
underlying pamidronate-based therapy, our in vitro data demonstrated that its antiviral
effects were partly mediated by IFN-γ secreted from human Vδ2-T cells. Meanwhile, human
Vδ2-T cells could directly kill virus-infected host cells in a perforin-, granzyme B- and
CD137-dependent manner. As pamidronate has been used for osteoporosis treatment for
more than 20 years, pamidronate-based therapy represents for a safe and readily available
option for clinical trials to treat H7N9 infection.
PLOS ONE | DOI:10.1371/journal.pone.0135999 August 18, 2015 1 / 15
a11111
OPEN ACCESS
Citation: Zheng J, Wu W-L, Liu Y, Xiang Z, Liu M,
Chan K-H, et al. (2015) The Therapeutic Effect of
Pamidronate on Lethal Avian Influenza A H7N9 Virus
Infected Humanized Mice. PLoS ONE 10(8):
e0135999. doi:10.1371/journal.pone.0135999
Editor: Adrianus CM Boon, Washington University
School of Medicine, UNITED STATES
Received: April 25, 2015
Accepted: July 28, 2015
Published: August 18, 2015
Copyright: © 2015 Zheng et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported in part by
General Research Fund, Research Grants Council of
Hong Kong (HKU 780113M), Area of Excellence
program on Influenza (AoE/M-12/06) of Hong Kong
SAR, China, and Dr. Richard YH Yu. The funders had
no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Introduction
The first human epidemic of avian-origin influenza virus infection caused by subtype H5N1
occurred in 1997 [1]. In February 2013, a novel avian-origin influenza A virus H7N9 was firstly
identified in patients in Eastern China [2–6]. During the first wave of H7N9 infection among
human population in 2013, 143 patients with 46 deaths were confirmed in 11 provinces or
municipalities in China, leading to the concern of a new influenza pandemic. Although the lim-
ited human-human transmission of H7N9 virus decreased the possibility of a global pandemic,
the return of H7N9 infection trend in early 2014 aroused the concentrations on improving the
control and treatment of newly-occurred avian influenza virus [7]. On the other hand, com-
mercial antiviral drugs such as oseltamivir and zanamivir are generally effective in reducing
viral load and improving clinical outcome once being administrated within 48 hours post
symptom onset, but are less effective in severe cases who are often presented late [8]. Moreover,
H7N9 strains carrying Arg292Lys mutation in neuraminidase [6] gene were identified in two
H7N9-infected patients recently and exhibited resistance to the treatment of adamantanes,
oseltamivir and zanamivir [9], which made developing alternative therapeutic strategies to
treat H7N9 infection in urgent need.
As the first line of host immune defense system, innate immunity plays a critical role in
the early defense against influenza A virus infections. More importantly, innate immunity-
targeted strategy shows advantage over the virus-targeted therapy in avoiding the failure of
treatment due to frequent antigen drift and shift as seen in influenza virus [10]. Although
only representing for 1–10% of T lymphocytes in peripheral blood of adult humans and ani-
mals, γδ-T cells have been confirmed to be an important component of innate immunity and
equipped with broadly antiviral and anti-tumor capabilities [11,12]. In humans, more than
95% of γδ-T cells in peripheral blood and lymphoid organs are Vδ2-T cells. As human Vδ2-T
cells could be specifically activated and expanded in an HLA unrestricted manner by small
non-peptidic phosphoantigens [13], this minor population of peripheral T lymphocyte repre-
sents for a potential target in antiviral and anti-tumor therapy. In previous reports, we have
shown that pamidronate, a pharmacological phosphoantigen currently used in treating oste-
oporosis, exhibited protective effects against influenza infection caused by seasonal H1N1
and avian H5N1 viruses in both in vitro and in vivo models [14–17]. We also demonstrated
that the antiviral effects of pamidronate were dependent on Vδ2-T cells and mediated by
their cytokine secretion and cytotoxicity against virus-infected host cells [14–17]. However,
direct comparison between the efficacies of pamidronate with conventional antiviral drugs is
still lack.
In this study, using a fatal H7N9 infection model established on humanized mice, we com-
pared the therapeutic effects of oseltamivir and pamidronate administrated according to their
clinical application. It was demonstrated that, compared to oral treatment of oseltamivir, intra-
peritoneal (i.p.) injection of pamidronate could significantly reduce the severity of H7N9 infec-
tion and improve the survival rate of infected mice by enhancing Vδ2-T cell-mediated
immunity. More importantly, pamidronate treatment starting 3 days post infection could still
decrease disease severity and the mortality, whereas oseltamivir treatment starting at this time
frame showed no such therapeutic effect. Meanwhile, we further investigated the molecular
mechanisms underlying Vδ2-T cell-mediated antiviral effects in in vitro primary culture sys-
tem, and found that IFN-γ, perforin, Granzyme B and CD137 expressed by Vδ2-T cell played
important roles in this antiviral effect. Our study suggested a new therapeutic option for treat-
ing H7N9 virus infection.
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Materials and Methods
Generation of Humanized Mice
Rag2−/−γc−/−mice were purchased from Taconic and maintained in individual ventilated cages
(IVC) system under specific pathogens-free (SPF) environment in the Laboratory Animal
Unit, the University of Hong Kong. Human PBMCs were isolated from buffy coat preparations
of blood from healthy donors collected by the Hong Kong Red Cross with written consent.
Humanized mice were established in 4 weeks old Rag2−/−γc−/−mice by i.p. transplanting
30×106 human PBMCs as we described previously [17,18]. These chimeric Rag2-/-γc-/- mice
had functional human T and B cells including similar percentage of circulating Vδ2+ T cells
compared to human after 4 weeks of PBMC transplantation and thus were referred to as
“humanized” mice. All manipulations on animals were performed in compliance with the Ani-
mals (Scientific Procedures) Act, 1986 (UK) (amended in 2013) and approved by the Commit-
tee on the Use of Live Animals in Teaching and Research (CULATR), Hong Kong (approval
number: CULATR 2378–11). All sections of this report adhered to the ARRIVE Guidelines for
reporting animal research and a completed ARRIVE guidelines checklist was included in S1
Checklist. All manipulations on human PBMCs were approved by the Institutional Review
Board (IRB) of the University of Hong Kong/Hospital Authority Hong Kong West Cluster,
Hong Kong (approval number: UW07-154).
Viruses, Infections, and Treatment of Virus-Infected Humanized Mice
Avian influenza virus H7N9 (A/Zhejiang/DTID-ZJU01/2013) were cultured in SPF eggs and
the viral titer was determined by daily observation of cytopathic effect in MDCK infected with
serial dilutions of virus stock; median tissue culture infective dose (TCID50) was calculated
according to the Reed-Muench formula. Humanized mice were separated into corresponding
groups based on matched sex, weight, and the source of human PBMCs before infection with
H7N9 virus (25μl, 106, 104, and 102TCID50 respectively) via intra nasal (i.n.). For intervention
studies, a human equivalent dose of pamidronate (Pamisol; Hospira Australia Pty Led) or
saline of equivalent volume was injected i.p. on day 1 (10mg/kg body weight) and day 3, 5
(5mg/kg per dose) post infections, while oseltamivir (kindly provided by F.Hoffmann-La
Roche Ltd, Basel, Switzerland) or saline of equivalent volume was given by oral gavage at
50mg/kg twice a day for 5 consecutive days since day 0 post infection [19]. For delayed-treat-
ment, Pamidronate were injected i.p. on day 3 (10mg/kg), 5, 7 and 9 (5mg/kg per dose) post
infections, while oseltamivir-treated mice were given oseltamivir at 50mg/kg by oral gavage
twice a day for 5 consecutive days (day 3–7 post infection). 5–6 mice per group were used for
each independent experiment while all experiments were replicated 1–2 times for obtaining
unbiased data with the minimum quantity of used animals. Mice with>30% weight loss were
sacrificed and counted as death.
In all animal experiments, mice will be monitored twice a day during the whole process,
while food and water was placed in cages for them to obtain easily. Meanwhile, soft and clean
bedding, quiet environment and circadian light will be provided to reduce animal stress. No
unexpected death occurred during this study and mice were euthanized by cervical dislocation
under anesthesia (by i.p. injection of ketamine plus xylazine at the final concentration of
7.5mg/kg and 0.88mg/kg respectively) when the study was completed or one of the following
conditions was observed: body weight loss>30%; body temperature±>2°C; cardiac/respiratory
rate±>50%; signs of severe pneumonia (very weak and pre-comatose). To minimize animal
suffering and distress, all invasive manipulations will be carried out under anesthesia as
described above.
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Immunohistochemistry Assays of Lungs
The lungs from infected humanized mice were harvested on day 5 or 7 post infection, fixed
with 10% formalin, and maintained in 75% ethanol. Paraffin-embedded lung sections were pre-
pared according to standard protocols and stained with hematoxylin and eosin. All lung sec-
tions were screened, and five fields of each sample were selected randomly by 2 independent
observers for evaluating the levels of pathology among different groups.
Determination of Virus Copy, Inflammatory Cytokines/Chemokines in
Lungs
The lungs from infected humanized mice were harvested on day 1, 3, 5 or 7 post infection and
homogenized in 2 ml of PBS. After centrifugation at 1,500 g for 15 min, the supernatants were
collected for the determination of viral load and inflammatory cytokines, chemokines. The
concentrations of human cytokines and chemokines were detected and analyzed with human
cytokine and chemokine assay kits (Bender MedSystems).
Generation of Pamidronate-Expanded Vδ2-T Cells and MDMs
Human PBMCs were cultured in 10% FBS RPMI-1640 medium with 9μg/ml of pamidronate.
Recombinant human IL-2 (Invitrogen) was added into the medium at the final concentration
of 500IU/ml every 3 d from day 3. After 14-d culture, Vδ2-T cells were purified by positive
selection with anti-human TCR γ/δ+ T cell microbeads according to the manufacturer’s
instruction (Miltenyi Biotec). Human Monocyte-derived macrophages (MDMs) were gener-
ated from monocytes. Briefly, adherent monocytes were cultured in RPMI-1640 supplemented
with 5% autologous serum and allowed to differentiate to macrophages for 14 d.
Cytotoxic Assay
Human MDMs (Target, T) were stained with Carboxyfluorescein succinimidyl ester (CFSE)
and infected with H7N9 influenza virus at multiplicity of infection (MOI) of 2 before co-cultur-
ing with autologous Vδ2-T cells (Effector, E) at different E:T ratios for 6 h. Cells were then
stained with ethidium homodimer-2 (EthD-2) to identify dead ones. The cytotoxicity of Vδ2-T
cells against virus-infected MDMs was assessed by flow cytometry as the percentage of EthD-
2+ cells in CFSE+ population with FACSAria (BD) and FlowJo software (Tree Star) (S1 Fig).
Quantification of Viral Copies by RT-PCR
Human MDMs were infected by H7N9 virus at MOI of 2. 1 h later, un-adsorbed virus was
washed away carefully and MDMs were cultured alone or with Vδ2-T cells for 48 h. Then the
cells and supernatant were harvested for extraction of total RNA by TRIzol LS reagent accord-
ing to the manufacturer’s instructions (Invitrogen). The cDNA was synthesized with oligo
(dT)12-18 primer and Superscript II reverse transcription (Invitrogen). Viral matrix gene copies
were quantified on the basis of SYBR green fluorescence signal after real-time PCR procedure
(forward primer, 50-CTTCTAACCGAGGTCGAAACG-30; reverse primer, 50-GGCATTTTGGA
CAAAGCGTCTA-30) by ABI PRISM 7900 Sequence Detection System (Applied Biosystems).
Results were expressed as the number of target gene copies per 103 MDMs.
Blocking Assay
Vδ2-T cells were co-cultured with H7N9 virus–infectedMDMs at indicated E:T ratio. The neu-
tralization antibodies mouse anti-human NKG2D (monoclonal; clone number: 1D11; BD),
mouse anti-human FasL (monoclonal; clone number: 100419; R&D Systems), mouse anti-human
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TRAIL (monoclonal; clone number: RIK-2; R&D Systems), mouse anti-human CD137 (mono-
clonal; clone number: 4B4-1, Biolegend), mouse anti-human CD244 (monoclonal; clone number:
2–69; BD), goat anti-human IFN-γ (polyclonal; R&D Systems) and their relevant isotype controls
(IC) were used at the final concentration of 10μg/ml. For blocking perforin and granzyme B, MA
(Sigma-Aldrich) and Bcl-2 (R&D Systems) were used respectively. The cytotoxicity were then cal-
culated by CFSE and EthD2 staining as described previously.
Statistical Analyses
Data are presented by means ± SEM. Multiple regression analysis was used to test the differ-
ences in the body weight changes between different groups adjusted for time after infection.
The differences in cytotoxicity and virus copy for in vitro experiments, and viral load or con-
centrations of pro-inflammatory cytokines/chemokines were analyzed by unpaired two-tailed
Student’s t test. The P value of the difference for survival was determined by Kaplan-Meier log-
rank test. P<0.05 was considered to be significant.
Results
Avian Influenza A H7N9 Virus Caused Severe Disease in Humanized
Mice
We firstly examined the pathogenic effects of H7N9 virus by i.n. infecting humanized mice
with different doses of H7N9 virus. As shown in Fig 1, low dose (102TCID50) of virus only
induced mild disease in humanized mice with evidence of 5–10% weight loss post infections.
In contrast, medium (104TCID50) or high (10
6TCID50) doses of virus caused rapid, severe and
irreversible weight loss in humanized mice (Fig 1). 33.3% of mice in medium dose of virus-
infected group could survive through 15 days post infection, while mice in high dose infection
group started to die from day 3 and all mice died within 12 days post infection (Fig 1). We thus
chose 106TCID50 (high dose) as the dose for establishing severe and fatal H7N9 influenza virus
challenge model for the following experiments.
Pamidronate Exhibited Superior Effects on Controlling H7N9 Infection in
Humanized Mice Compared to Oseltamivir
To compare therapeutic effects of pamidronate and oseltamivir on H7N9-infected humanized
mice, pamidronate-treated mice were i.p. injected with one full dose drug (10mg/kg) on day 1
Fig 1. Induction of severe H7N9 infection in humanized mice.Humanized mice were infected with H7N9 virus i.n. at different dose (106, 104, 102 TCID50)
in 25μl of saline solution on day 0. The weight change (A) and survival (B) in virus-infected mice (5 mice per group) were monitored and recorded till day 15
post infection.
doi:10.1371/journal.pone.0135999.g001
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post infection, and one half dose (5mg/kg) on day 3 and 5 respectively, while oseltamivir-
treated group was given drug by oral gavage twice a day (50mg/kg per dose) for 5 consecutive
days (day 0–4 post infection). Saline of same volume was given as control by respective ways
(Fig 2A). As shown in Fig 2B and 2C, all mice in untreated group and saline-treated groups
had comparably rapid and irreversible weight loss and death within 12 days post virus infec-
tion. Although the treatment of oseltamivir ameliorated the fast weight loss of infected mice
during the early phase of infection, no significant improvement in survival of infected mice
could be obtained. In contrast, treatment with pamidronate significantly improved the progno-
sis of infected humanized mice as evidenced by decreased weight loss and mortality. These
results demonstrated that pamidronate could effectively ameliorate disease severity and the
mortality caused by H7N9 virus compared to oseltamivir.
To illustrate molecular mechanisms underlying superior performance exhibited by pami-
dronate compared to oseltamivir, we examined the viral load, pro-inflammatory cytokines and
Fig 2. Effects of oseltamivir and pamidronate on lethal H7N9 infection in humanizedmice. A. Protocol of assessing effects of oseltamivir and
pamidronate on lethal H7N9 infection in humanized mice. Humanized mice established from PBMCs of same donors were infected with H7N9 virus i.n.at 106
TCID50 in 25μl of saline solution on day 0 and distributed to corresponding groups. Pamidronate (i.p.-pamidronate group) or saline of equivalent volume (i.p.-
saline group) was injected i.p. on day 1 (10mg/kg), 3 and 5 (5mg/kg per dose) post infection whereas 50mg/kg oseltamivir (oral-oseltamivir group) or saline of
equivalent volume (oral-saline group) was given by oral gavage twice a day for 5 consecutive days since day 0 post infection. The weight change (B) and
survival (C) of virus-infected mice (6 mice per group) were monitored and recorded till day 15 post infection. The data are representative of three independent
experiments.
doi:10.1371/journal.pone.0135999.g002
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chemokines in the lungs of mice from pamidronate-treated, oseltamivir-treated and untreated
groups. As shown in Fig 3A, although both pamidronate and oseltamivir treatment reduced
the viral load in the lungs compared to untreated group, viral load in the lungs of pamidronate-
treated mice was significantly lower than that of oseltamivir-treated mice on day 5 post
Fig 3. Pamidronate exhibited superior effects in controlling virus replication and inflammation in
lungs of H7N9-infected humanized mice.Humanized mice were infected and treated as described
previously, while viral loads in the lungs will be determined on day 0, 1, 3, and 5 post infection (A). On day 5
post infection, lungs of H7N9-infected humanized mice from untreated, i.p.-pamidronate and oral-oseltamivir
group were harvested and the levels of human pro-inflammatory cytokines (B) and chemokines (C) in the
supernatants of homogenized lungs were determined (n = 5). *p<0.05; n.s., no significance; detection limits:
IL-8: 14~10,000pg/ml; MCP-1: 55~40,000pg/ml; IP-10: 17~12,500pg/ml; IL-1β, IL-2, IL-10, IL-12, IFN-γ, and
TNF-α: 27~20,000pg/ml; IL-17A: 14–10,000pg/ml. (D) Representative histological sections of the lung
tissues from H7N9 virus-infected mice receving pamidronate or saline treatment were stained with
hematoxylin and eosin. Bars, 100μm. The data are representative of three independent experiments.
doi:10.1371/journal.pone.0135999.g003
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infection. Moreover, pamidronate treatment significantly reduced the levels of human IL-1β,
IL-2, IL-12, TNF-α and MCP-1 in the lungs as compared to other treatments (Fig 3B and 3C).
Furthermore, less infiltration of leukocytes and moderate pathology were observed in the lungs
of pamidronate-treated humanized mice on day 5 post-infection compared with that of
untreated mice, whereas oseltamivir treatment exhibited no effects on controlling severe lung
inflammation caused by infection (Fig 3D). Taken together, these results indicated that pami-
dronate treatment could inhibit H7N9 virus replication in the lung and attenuate the lung
inflammation and pathology, thus exhibited superior potential in controlling H7N9 infection
in humanized mice compared to oseltamivir.
Pamidronate Exhibited Better Therapeutic Effects than Oseltamivir by
Delayed Treatment
Since the onset of symptoms in H7N9-infected patients generally occurred on 2–3 days post
initial infection, we further evaluated the efficacy of pamidronate versus oseltamivir in human-
ized mice with severe diseases while being administrated at delayed time frame (Fig 4A). In
concert with clinical situation, H7N9-infected humanized mice exhibited abrupt weight loss
(approximately 15% of original weight) accompanied with intense inflammation and virus rep-
lication in lungs on day 3 post infection (Fig 4B and S2 Fig). Similar to early-treated mice, late
pamidronate-treated group was given one full dose drug (10mg/kg) on day 3 post infection
and one half dose (5mg/kg) on day 5, 7, and 9 respectively, while oseltamivir-treated group was
given oseltamivir orally twice a day (50mg/kg per dose) for 5 consecutive days (day 3–7 post
infection). As shown in Fig 4B and 4C, all mice in saline-treated group and oseltamivir-treated
group continuously lost their weight and died within 10 days post infection, and there were no
significant differences in weight loss and survival among these groups. In contrast, in pamidro-
nate-treated group, the weight loss of mice was ameliorated significantly and 50% of mice
recovered during 15 days post infection. These data suggested that pamidronate might be more
potent in treating severe influenza disease caused by H7N9 virus compared to oseltamivir,
especially for those who presented symptoms late.
To directly compare the efficacy of delayed pamidronate and oseltamivir treatment on virus
replication and lung inflammation, we also determined the viral load, pro-inflammatory cyto-
kines and chemokines, and pathology in the lungs. Consistent with that seen in early treatment
groups (Fig 3), H7N9 viral loads in the lungs from pamidronate-treated mice were significantly
lower than those in the lungs from oseltamivir-treated mice (Fig 4D). Meanwhile, pamidronate
treatment significantly reduced the levels of human IL-2, IL-12, IL-17A, TNF-α and MCP-1 in
the lungs compared to oseltamivir treatment (Fig 4E and 4F). Finally, there were fewer infil-
trated leukocytes and less pathology in the lungs from pamidronate-treated mice on day 7 after
H7N9 virus infection compared with that of oseltamivir-treated mice (Fig 4G).
Cellular and Molecular Mechanisms Underlying Protective Effects of
Pamidronate
Previously we have demonstrated that the control of influenza virus infections by pamidronate
was mediated by human Vδ2-T cells in both cytolytic and non-cytolytic manners [13,17]. To
clarify the mechanisms underlying the antiviral activity of pamidronate, pamidronate-
expanded human Vδ2-T cells were co-cultured with H7N9 virus-infected autologous human
MDMs. As shown in Fig 5A and 5B, Pamidronate-expanded Vδ2-T cells exhibited potent cyto-
toxic activity against H7N9 virus-infected MDMs and significantly inhibited virus replication
in MDMs. Using neutralizing antibodies against IFN-γ, we found that the inhibition of H7N9
virus replication was partially but significantly abrogated by anti-IFN-γ neutralizing antibody
Pamidronate Treat Lethal H7N9 Infection
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Fig 4. Therapeutic effects of Pamidronate and oseltamivir by delayed treatment. Humanized mice were infected with H7N9 virus i.n. at 106 TCID50 in
25μl saline solution on day 0. Pamidronate were injected i.p. on day 3 (10mg/kg), 5, 7 and 9 (5mg/kg per dose) post infection whereas control mice were fed
with oseltamivir by oral gavage daily for 5 consecutive days (day 3~7, 50mg/kg each dose) (A). The weight change (B) and survival (C) of infected mice (8
mice for pamidronate treatment group, 8 mice for oseltamivir treatment group, 6 mice for each saline-treated group) were monitored and recorded till day 15
post infections. On day 7 post infection, lungs from different groups were harvested and the viral loads (D) and the levels of human pro-inflammatory
cytokines (E) and chemokines (F) in the supernatants of homogenized lung tissue were determined (n = 5). *p<0.05; n.s., no significance; u.d., undetectable;
detection limits: IL-8: 14~10,000pg/ml; MCP-1: 55~40,000pg/ml; IP-10: 17~12,500pg/ml; IL-1β, IL-2, IL-10, IL-12, IFN-γ, and TNF-α: 27~20,000pg/ml; IL-
17A: 14–10,000pg/ml. (G) Representative histological sections of the lung tissues from H7N9 virus-infected mice receiving pamidronate or oseltamivir
treatment were stained with hematoxylin and eosin. Bars, 100μm. The data are representative of three independent experiments.
doi:10.1371/journal.pone.0135999.g004
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(Fig 5B), indicating that pamidronate-expanded Vδ2-T cells could inhibit H7N9 virus replica-
tion in host cells in a IFN-γ-dependent manner. Consistent with our previous report, the cyto-
toxic activities of Vδ2-T cells against H7N9 virus-infected MDMs were significantly abrogated
by the combination of CMA and Bcl-2 treatment [16]. Interestingly, anti-CD137, instead of
anti-TRAL, anti-FasL, anti-NKG2D or anti-CD244, blocking antibody treatment exhibited sig-
nificant inhibition on Vδ2-T cell-mediated cytotoxicity (Fig 5C). Taken together, our data
demonstrated that pamidronate-expanded Vδ2-T cells could exhibit both non-cytolytic and
cytotoxic antiviral activities against H7N9 virus.
Fig 5. Pamidronate-expanded Vδ2-T cells exhibited both non-cytolytic and cytotoxic antiviral
activities against H7N9 virus infection. HumanMDMs (target, T) were infected with H7N9 virus or mock at
MOI of 2 for 1 hour, and then co-cultured with pamidronate-expanded autologous Vδ2-T cells (effector, E) at
indicated E:T ratios for 6 hours. The cytotoxicity of Vδ2-T cells was determined by EthD2 staining on dead
MDM at the final 15 minutes of co-culture (A). To determine whether IFN-γ released from Vδ2-T cells was
involved in the inhibition of viral replication, Vδ2-T cells and virus-infected MDMs were co-cultured at 1:1 of E:
T ratio for 48 hours in the presence of IFN-γ neutralizing antibody (10μg/ml) and its isotype control (IC, goat
IgG) respectively. The virus copies (B) in the co-culture were then determined by qPCR (n = 4). (C)
Pamidronate-expanded Vδ2-T cells were co-cultured with virus-infected MDMs at a E:T ratio of 10: 1 for 6 h.
The perforin inhibitor CMA and granzyme B inhibitor Bcl-2 (both at 1μg/ml), anti-NKG2D (aNKG2D), anti-
TRAIL (aTRAIL), anti-FasL (aFasL), anti-CD137 (aCD137), anti-CD244 (aCD244) blocking antibodies (all at
10μg/ml), or their relevant isotype controls were added into the culture since the initiation of incubation. The
death of virus-infected MDMs was analyzed by flow cytometry. *p<0.05; **p<0.01; n.s., no significance.
doi:10.1371/journal.pone.0135999.g005
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Discussion
Humanized mice model, as a powerful and cost-effective animal model, has been widely used
for studying human innate and adaptive immunity against infectious diseases [20,21]. As intro-
duced previously [17], the humanized mice established in our lab by transplantation with
human PBMCs were equipped with functional human CD4+, CD8+ T cells, NK cells and B
cells, which could sustain over one year. More importantly, these mice contained a similar per-
centage of Vδ2-T cells in peripheral blood compared to that in humans [17]. As there are no
Vδ2-T cells in mice or ferret, humanized mice provide a satisfactory translational platform for
investigating human Vδ2 T cell-mediated immune response in vivo. Meanwhile, we also have
confirmed that influenza virus could efficiently replicate in the respiratory system and cause
pathology in humanized mice [17]. In this study, by using humanized mice model, we estab-
lished a H7N9 infection model accompanied with typical characteristics of serious or fatal
human influenza infection including severe inflammation and infiltration of leukocytes,
intense expression of pro-inflammatory cytokines and chemokines in the lung, rapid weight
loss and death. Compared with other investigations using normal mice [22], pigs and ferrets
[23] as animal model, humanized mice might represent for better models in exploring novel
immune therapy against severe H7N9 infection in human.
Although the benefits of human Vδ2-T cells in defense against some virus infections have
been confirmed in clinical and experimental studies, their applications in treating infectious
diseases were hampered by their scarcity in circulation [11,24–26]. Phosphoantigen, a small
compound produced through mevalonate pathway that could specifically expand and activate
Vδ2-T cells both in vitro and in vivo, made Vδ2-T cell-based therapy possible. In this study, we
demonstrated that pamidronate, a commercially pharmacological phosphoantigen that has
been commonly used for the treatment of osteoporosis for more than two decades [11,24],
could effectively control H7N9 virus-caused severe disease in humanized mice through inhibit-
ing virus replication and ameliorating inflammation in the affected lungs. This beneficial effect
was mediated by boosting human Vδ2-T-cell-mediated immunity, because no such protective
effect could be identified in Vδ2-T cell-deficient humanized mice [17]. Indeed, the ability of
pamidronate to control disease caused by H7N9 influenza virus was found to largely depend
on the initial quantity of Vδ2-T cells in peripheral blood of humanized mice before therapy. As
shown in S3 Fig, One H7N9 virus-infected humanized mice which had low percentage of
Vδ2-T cells (<1% of circulating T lymphocytes) eventually died on day 10 post infection
despite receiving pamidronate treatment since day 1 post infection. In contrast, other H7N9
virus-infected humanized mice (>1% of circulating T cells being Vδ2-T cells) all recovered
after the same treatment with pamidronate, which supported the indispensable role of Vδ2-T
cells in pamidronate treatment and indicated that the initial number of Vδ2-T cells might be
an important index to evaluate the prognosis of pamidronate-treated patients.
Consistent with previous reports [14,16], here we demonstrated that Vδ2-T cells could
exhibit IFN-γ-mediated non-cytolytic ability in inhibiting virus replication. Meanwhile, we
also showed that Vδ2-T cells could directly kill H7N9 virus-infected cells, and their cytolytic
function was mainly mediated by perforin-granzyme B pathway. Interestingly, it was found
that instead of TRAIL, FasL and NKG2D, which were found to be involved in cytotoxicity
against seasonal H1N1 and H9N2-infected host cells [13,17], CD137 played an important role
in Vδ2-T cell-mediated cytotoxicity against H7N9-infected MDMs. Although these results
could not be directly translated into the mechanisms underlying Vδ2-T cell-mediated protec-
tion on H7N9-infected humanized mice due to species gap, they undoubtedly improved our
understanding on distinct pathways applied by immune system against different influenza
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virus infections and provided some novel targets for designing specific therapy against unique
influenza virus infection.
Resistance to both oseltamivir and zanamivir has been reported for H7N9 virus strains
[9,27]. In addition, traditional antivirals are less effective in severe cases, especially when the
administration of antiviral therapy was delayed [8]. More recently, clinical meta-analysis also
suggested that oseltamivir had only limited effect on clinical symptoms and did not reduce hos-
pitalization or serious complications of influenza infections [28]. Distinct from these tradi-
tional strategies, the treatment of pamidronate could expand and activate Vδ2-T cells rather
than targeting the virus per se, and thus reduced the emergence of drug-resistant strains. In
this study, by directly comparing efficacies of pamidronate versus oseltamivir administrated
according to their clinical application, we showed that i.p. injection of pamidronate exhibited
better effects in controlling viral replication and inflammatory damage caused by H7N9 virus
than oseltamivir fed by oral gavage. As shown in Fig 2, although the oseltamivir treatment
could ameliorate the weight loss of infected mice during the early phase (Day 0 to 5 post infec-
tion), it could not reverse the final outcome of infected humanized mice. Actually, the inflam-
mation in lungs of oseltamivir-treated mice had been severe on day 5 post infection in spite of
lower viral load in lungs compared to that of untreated mice and similar weight loss compared
to that of pamidronate-treated mice (Figs 2 and 3), which suggested that even preventive treat-
ment of oseltamivir had only marginal effects on controlling H7N9 virus infection. In contrast,
pamidronate exhibited apparent therapeutic effects on H7N9 infection even being given since
a late time points (starting from day 3 post infection) (Fig 4), which strongly supported their
potential in treating confirmed patient in clinic.
Besides NA inhibitors family, ventilatory support, extracorporeal membrane oxygenation
[9,29] and systemic NA inhibitors treatment combined with ribavirin or protease inhibitor
aprotinin represented for key treatment modalities in treating H7N9 infections in clinical prac-
tice. However, the side effects of ribavirin and aprotinin were prohibitive to their clinical use
[30,31]. On the other hand, the efficacy of typical antivirals by sialidase DAS181 [32] might be
largely attenuated in established pneumonic consolidation following severe inflammation.
Although treatments with high titer specific neutralizing antibodies collected and purified
from convalescent-phase plasma or intravenous immunoglobulin appeared effective for treat-
ing H1N1 of 1918, 2009 and H5N1 infections, convalescent H7N9 donors that could be
recruited are still lacking [33,34]. Non-specific anti-inflammatory recipes such as steroids, stat-
ins, and macrolides could decrease the pathology in infected lungs, but might dampen the
immune system of patients as well [35]. Finally, delayed treatment with a combination of Cox2
inhibitors and zanamivir was shown to improve survival in A (H5N1) infected mice model
[36], but its application in human still need to be evaluated in clinic. Compared to above strate-
gies, Vδ2-T cell-targeted pamidronate treatment exhibited satisfactory control in both viral
replication and inflammatory damage, which made it a more promising strategy in future clini-
cal practice.
In conclusion, our study demonstrated that pamidronate could control H7N9 virus infec-
tion in humanized mice even by delayed treatment. As pamidronate has been commonly used
for treating osteoporosis in clinic for over 20 years, this ‘new application of an old drug’ strat-
egy potentially offers a safe and readily available option for the treatment of H7N9 virus
infection.
Supporting Information
S1 Checklist. Completed ARRIVE Guidelines checklist for reporting animal research.
(DOCX)
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S1 Fig. Gating strategy of flow cytometry data on cytotoxicity assay. Total cells in the co-cul-
ture of Vδ2-T cells and H7N9 virus–infected MDMs were sorted by forward scatter (FSC) and
side scatter (SSC) firstly. MDMs were then gated as CFSE+ population, in which EthD-2+ cells
represented for dead target cells killed by Vδ2-T cells.
(TIF)
S2 Fig. Inflammation and virus copy in humanized mice on day 3 post infection with
H7N9.Humanized mice were infected with H7N9 virus i.n.at 106 TCID50 in 25μl saline solu-
tion on day 0. On day 3 post infection, lungs from virus-infected mice were harvested and the
levels of pro-inflammatory cytokines (A) and chemokines (B) and the viral loads (C) in the
supernatants of homogenized lung tissue were determined (n = 3). Representative histological
sections of the lung tissues from H7N9 virus-infected mice on day 3 post infection were stained
with hematoxylin and eosin. Bars, 100μm. The data are representative of three independent
experiments.
(TIF)
S3 Fig. The correlation of initial quantity of peripheral Vδ2-T cells with the weight loss and
survival of humanized mice. Pamidronate-treated humanized mice as shown in Fig 2 were
grouped according to the initial percentage of Vδ2-T cells in peripheral CD3+ T cells. Their
weight change (A) and survival (B) were shown here.
(TIF)
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